Key result
Torcetrapib plus atorvastatin increases major cardiovascular events ~25% vs atorvastatin alone.
Why the study?
Does torcetrapib added to atorvastatin reduce major cardiovascular events in patients at high cardiovascular risk?
RCT (n=15,067)
Double-blind
Randomized
Does torcetrapib added to atorvastatin reduce major cardiovascular events in patients at high cardiovascular risk?
Despite improving lipid profiles, torcetrapib significantly increased the risk of cardiovascular events and all-cause mortality in high-risk patients, leading to premature trial termination.
Answers are grounded in this paper and cite their sources.
Precludes torcetrapib use; challenges CETP inhibition as a strategy to reduce cardiovascular risk.
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Barter et al. (2007) conducted an RCT in High cardiovascular risk (n=15,067). Torcetrapib plus atorvastatin vs. Atorvastatin alone was evaluated on Time to first major cardiovascular event (death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina) (HR 1.25, 95% CI 1.09-1.44, p=0.001). Torcetrapib plus atorvastatin increased major cardiovascular events and all-cause death vs atorvastatin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: